BIO-TECHNE Corp (NASDAQ:TECH) hit a new 52-week high during trading on Tuesday . The company traded as high as $203.50 and last traded at $201.04, with a volume of 4192 shares changing hands. The stock had previously closed at $201.13.

A number of equities research analysts have commented on TECH shares. Zacks Investment Research cut BIO-TECHNE from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 15th. Craig Hallum raised their price objective on BIO-TECHNE from $160.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. BidaskClub cut BIO-TECHNE from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 28th. Argus started coverage on BIO-TECHNE in a research note on Friday, June 15th. They issued a “buy” rating and a $185.00 price objective for the company. Finally, Citigroup raised their price objective on BIO-TECHNE from $160.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $185.57.

The stock has a market cap of $7.56 billion, a PE ratio of 49.51, a P/E/G ratio of 3.40 and a beta of 0.88. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.01 and a quick ratio of 3.93.

BIO-TECHNE (NASDAQ:TECH) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported $1.34 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.29 by $0.05. The company had revenue of $180.25 million for the quarter, compared to analysts’ expectations of $176.24 million. BIO-TECHNE had a return on equity of 14.64% and a net margin of 19.50%. analysts predict that BIO-TECHNE Corp will post 3.92 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, August 31st. Investors of record on Friday, August 17th were given a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, August 16th. This represents a $1.28 annualized dividend and a dividend yield of 0.64%. BIO-TECHNE’s payout ratio is 31.45%.

In related news, Director John L. Higgins sold 10,000 shares of BIO-TECHNE stock in a transaction that occurred on Thursday, August 23rd. The stock was sold at an average price of $187.92, for a total transaction of $1,879,200.00. Following the transaction, the director now owns 13,012 shares of the company’s stock, valued at $2,445,215.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Charles A. Dinarello sold 5,000 shares of BIO-TECHNE stock in a transaction that occurred on Wednesday, August 8th. The shares were sold at an average price of $176.94, for a total value of $884,700.00. Following the transaction, the director now directly owns 13,212 shares in the company, valued at approximately $2,337,731.28. The disclosure for this sale can be found here. 3.80% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in TECH. Wells Fargo & Company MN boosted its position in shares of BIO-TECHNE by 3.7% during the first quarter. Wells Fargo & Company MN now owns 53,441 shares of the biotechnology company’s stock valued at $8,071,000 after buying an additional 1,882 shares during the last quarter. BlackRock Inc. boosted its position in BIO-TECHNE by 3.0% in the first quarter. BlackRock Inc. now owns 3,684,936 shares of the biotechnology company’s stock worth $556,573,000 after purchasing an additional 106,355 shares during the last quarter. Federated Investors Inc. PA boosted its position in BIO-TECHNE by 3.4% in the first quarter. Federated Investors Inc. PA now owns 15,460 shares of the biotechnology company’s stock worth $2,335,000 after purchasing an additional 510 shares during the last quarter. JPMorgan Chase & Co. boosted its position in BIO-TECHNE by 59.1% in the first quarter. JPMorgan Chase & Co. now owns 68,545 shares of the biotechnology company’s stock worth $10,353,000 after purchasing an additional 25,451 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its position in BIO-TECHNE by 3.4% in the first quarter. Great West Life Assurance Co. Can now owns 22,599 shares of the biotechnology company’s stock worth $3,413,000 after purchasing an additional 747 shares during the last quarter. 94.32% of the stock is currently owned by institutional investors.

About BIO-TECHNE (NASDAQ:TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Recommended Story: Diversification For Individual Investors

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.